ALK degrader 1 是一种强效的基于疏水标签技术 (HyT) 的降解剂,依赖泛素-蛋白酶体系统降解 EML4-ALK (DC50 = 0.13 μM),在 ALK 依赖性细胞系中表现出优越的 ALK 降解活性与抗增殖作用,但对 ALK 融合阴性细胞无明显细胞毒性,可诱导细胞发生 G0/G1 期周期阻滞并促进细胞凋亡 (apoptosis),不仅能高效降解 ALK 蛋白,还能阻断 STAT3 等关键下游信号轴,并在体内高效诱导 EML4-ALK 降解,适用于 ALK 相关疾病的研究。
ALK degrader 1
产品编号: MS-D14495 分子式: C39H47N5O2 分子量: 617.82
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ALK degrader 1 是一种强效的基于疏水标签技术 (HyT) 的降解剂,依赖泛素-蛋白酶体系统降解 EML4-ALK (DC50 = 0.13 μM),在 ALK 依赖性细胞系中表现出优越的 ALK 降解活性与抗增殖作用,但对 ALK 融合阴性细胞无明显细胞毒性,可诱导细胞发生 G0/G1 期周期阻滞并促进细胞凋亡 (apoptosis),不仅能高效降解 ALK 蛋白,还能阻断 STAT3 等关键下游信号轴,并在体内高效诱导 EML4-ALK 降解,适用于 ALK 相关疾病的研究。

生物实验数据

生物活性 ALK degrader 1 is a potent hydrophobic tag (HyT)-based degrader that relies on the ubiquitin-proteasome system to degrade EML4-ALK (DC50 = 0.13 μM), exhibits superior ALK degradation activity and antiproliferative effects in ALK-dependent cell lines without obvious cytotoxicity in ALK fusion-negative cells, induces G0/G1 phase cell cycle arrest and promotes apoptosis (apoptosis), not only efficiently degrades ALK protein but also blocks key downstream signaling axes such as STAT3, and efficiently induces EML4-ALK degradation in vivo, making it suitable for research on ALK-related diseases.
体外研究
(In Vitro)

ALK degrader 1 (compound H7) (72 小时) 在 ALK 依赖性细胞系中表现出抗增殖作用,在 H3122 细胞中的 IC50 为 0.23 μM,在 Karpas 299 细胞中的 IC50 为 0.19 μM。
ALK degrader 1 (0.5-5 μM,24 小时) 可有效降解 H3122 细胞中的 EML4-ALK,在0.5 μM 下即可实现超过 80 %的降解;而在 Karpas 299 细胞中对 NPM-ALK 的降解活性相对较弱,在 5 μM 下降解率约为 70 %。
ALK degrader 1 (0.1-5 μM,2-24 小时) 是一种强效的 EML4-ALK 降解剂 (DC50 = 0.13 μM),具有快速、持续的降解特性,可有效抑制 H3122 细胞中的 ALK 磷酸化和下游 STAT3 信号通路。
ALK degrader 1 (2 μM,24 小时) 在撤药后,仍能维持 EML4-ALK 的降解效果达 48 小时。
ALK degrader 1 (0.5-2 μM,24 小时) 可有效抑制 H3122 细胞中的有丝分裂进程,引发 G0/G1 期停滞,从而诱导细胞凋亡。
ALK degrader 1 (2 μM,24 小时) 上调 ALK mRNA 表达,同时促进 ALK 与 Hsp70 的结合,其降解作用可被 MG-132 (MS-L06849) 显著抑制,表明该降解过程依赖于泛素-蛋白酶体系统。
ALK degrader 1 (0.1-1 μM,72 小时) 对 ALK 阴性肿瘤细胞 (A549) 和正常肺上皮成纤维细胞 (HFL-1) 表现出良好的选择性,且无明显毒副作用,表明其安全性良好。

Western Blot Analysis

Cell Line: H3122 and Karpas 299 cells
Concentration: 0.5, 1, and 5 μM
Incubation Time: 24 h
Result: Effectively degraded EML4-ALK in H3122 cells at 5 μM after 24 h.
Exhibited substantial EML4-ALK degradation efficacy even at 0.5 μM, with more than 80 % reduction observed in Karpas 299 cells.
Showed reduced degradation activity against NPM-ALK in Karpas 299 cells compared to its activity against EML4-ALK in H3122 cells.
Demonstrated appreciable NPM-ALK degradation in Karpas 299 cells, achieving approximately 70 % degradation at 5 μM.

Western Blot Analysis

Cell Line: H3122 cells
Concentration: 0.1, 0.5, 1, 2, and 5 μM
Incubation Time: 2, 4, 8, 16, 24 h
Result: Exhibited a concentration-dependent ability to degrade EML4-ALK in H3122 cells, with complete degradation observed and a DC50 of 0.13 μM.
Significant reduced ALK levels in H3122 cells at 0.5, 1 and 2 μM for 24 h.
Decreased ALK phosphorylation in H3122 cells at 0.1 μM.
Decreased p-STAT3 levels but did not change STAT3 levels in H3122 cells.
(2 μM)Induced effective and sustained degradation of EML4-ALK in H3122 cells, reaching approximately 30 % at 2 h, peaking by 4 h, maintaining suppression to 23 % at 24 h.

Western Blot Analysis

Cell Line: H3122 cells
Concentration: 2 μM
Incubation Time: 24 h
Result: Maintained low EML4-ALK levels for 48 hours after removal.

Cell Cycle Analysis

Cell Line: H3122 cells
Concentration: 0.5, 1, and 2 μM
Incubation Time: 24 h
Result: Significantly increased the G0/G1 phase cell population and reduced the G2 phase population compared to control after 24 h at 2 μM.
Significantly increased the sub-G0 phase cell population.

Apoptosis Analysis

Cell Line: H3122 cells
Concentration: 0.5, 1, and 2 μM
Incubation Time: 24 h
Result: Increased the proportion of apoptotic cells from 9.41 % to 21.07 % after 24 h at 2 μM.

Cell Proliferation Assay

Cell Line: H3122, HFL-1 and A549 cells.
Concentration: 0.1, 0.5, and 1 μM
Incubation Time: 72 h
Result: Inhibited H3122 cell proliferation by 30 % at 0.1 μM, while the inhibition rates for A549 and HFL-1 cells were 14 % and 12 %, respectively.
Iinhibited the proliferation of over 80 % of H3122 cells at 0.5 μM, but showed minimal activity against HFL-1 and A549 cells.
Exhibited a 90 % inhibition rate against H3122 cells at 1 μM, while its toxicity toward HFL-1 and A549 cells remained very low.
体内研究
(In Vivo)

ALK degrader 1 (20 mg/kg,静脉注射,单次给药) 可有效降解 H3122 异种移植小鼠模型中肿瘤组织中的 EML4-ALK 蛋白。

Animal Model: Female BALB/c nude mice (4 weeks old) subcutaneously inoculated with H3122 cells
Dosage: 20 mg/kg
Administration: i.v., once
Result: Exhibited sustained EML4-ALK degradation, detectable by 12 hours post-treatment and achieving over 85 % by 36 hours.

化学信息

分子量 617.82
分子式 C39H47N5O2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础